Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase II drugs for Cutaneous Squamous Cell Carcinoma (cSCC) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Fosifloxuridine nafalbenamide LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fosifloxuridine nafalbenamide overview
NuCana overview
NuCana is a clinical-stage biopharmaceutical company that develops novel and transformational medicines for the treatment of cancer. The company pipeline products include NUTIDE-302, NUTIDE-323, NUTIDE-303 and NUTIDE-701 under the clinical studies NUC-3373 and NUC-7738. The company’s product candidates treat colorectal cancer, solid tumor and lung cancer, among others. NuCana develops products based on the ProTide technology platform, which focuses on developing new-generation, anti-cancer agents. The company operates in UK and the US. NuCana is headquartered in Edinburgh, Scotland, the UK
For a complete picture of Fosifloxuridine nafalbenamide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.